BSI-706, Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors

BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor Efficacy

Discovery and Development of an Anti-CD40 Agonistic Antibody for Cancer Immunotherapy

BSI-508, a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy

BSI-507, a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy

BSI-001, a Novel Anti-HER2 Antibody Exhibiting Potent Synergistic Efficacy with Trastuzumab

BSI-082， a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations

BSI-060T，a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker